Epeius Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
News Feb 17, 2009
Epeius Biotechnologies Corporation has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body.
With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic (or disease-seeking) targeting. These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the USA for targeted gene delivery in vivo.
Together these clinical patents provide additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent Rexin-G®—the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.
Based on recent breakthroughs in tumor-targeting and nanotechnology, a new generation of biological anti-cancer agents that are highly selective for diseased tissues is currently in clinical development.
Anti-cancer agents such as Rexin-G® can be delivered by simple intravenous infusion, yet are programmed to seek-out and accumulate selectively in primary and metastatic lesions that have spread throughout the body, delivering a tumor-killing gene while sparing normal cells and tissues.
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE
Genetics Help Make a Weed a WeedNews
A study has has found that the success of weedy and invasive plants like the Jerusalem artichoke lies in their genes. Understanding how invasive plants evolve and the genes that enable them to thrive in a new environment is key to better understanding why they are wreaking havoc on natural landscapes and food production around the world.READ MORE